The rational design of a host material with strong adsorption and excellent electrical conductivity function for sulfur cathode to suppress the shuttle effects of soluble lithium polysulfide (LiPS) is crucial to advance the lithium-sulfur (Li-S) battery for future commercial applications. In this work, we designed a three-dimensional (3D) carbon fiber aerogel with graphene-like oxygenated carbon nitrogen (OCN) and TiO2 (OCNF-TiO2) as a sulfur anchoring material for Li-S battery and explored the regulating effects of TiO2 on the electrochemical performances. The OCNF-TiO2/S cathode presents an initial discharge-specific capacity of 1039 mAh/g (0.1C), a rate capacity of 690 mAh/g at 1C, a cycling performance with a capacitance retention of 72.1%, and the decay of 0.13% per cycle after 200 cycles at 0.5C.

Non-small-cell lung cancer (NSCLC) patients who experience brain metastases are usually associated with poor prognostic outcomes. This retrospective study proposed to assess whether bevacizumab or gefitinib can be used to improve the effectiveness of whole brain radiotherapy (WBRT) in managing patients with brain metastases. A total of 218 NSCLC patients with multiple brain metastases were retrospectively included in this study and were randomly allocated to bevacizumab-gefitinib-WBRT group (n=76), gefitinib-WBRT group (n=77) and WBRT group (n=75). Then, tumor responses were evaluated every 2 months based on Response Evaluation Criteria in Solid Tumors version 1.0. Karnofsky performance status and neurologic examination were documented every 6 months after the treatment. Compared to the standard WBRT, bevacizumab and gefitinib could significantly enhance response rate (RR) and disease control rate (DCR) of WBRT (P<0.001). At the same time, RR and DCR of patients who received bevacizumab-gefitinib-WBRT were higher than those who received gefitinib-WBRT. The overall survival (OS) rates and progression-free survival (PFS) rates also differed significantly among the bevacizumab-gefitinib-WBRT (48.6 and 29.8%), gefitinib-WBRT (36.7 and 29.6%) and WBRT (9.8 and 14.6%) groups (P<0.05). Although bevacizumab-gefitinib-WBRT was slightly more toxic than gefitinib-WBRT, the toxicity was tolerable. As suggested by prolonged PFS and OS status, bevacizumab substantially improved the overall efficacy of WBRT in the management of patients with NSCLC.